Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Research Question:
What is the impact of stem cell dose on outcome after autologous transplant?

Basic Study Information

Purpose:
Following enrollment, patients will be CD34+ stem cell mobilized with plerixafor, at the discretion of the treating attending physician, for the achievement of >6 x10^6 CD34+ cells/kg. The patients that fail to mobilize >6 x10^6 CD34+ cells/kg will not be randomized and will subsequently be followed for disease progression and overall survival. Patients with >6 x10^6 CD34+ cells/kg cryopreserved on study will be admitted to the hospital for planned autologous stem cell transplant (ASCT). Patients will be randomly infused with either 3-4 x 10^6 CD34+ stem cells/kg or 6-8 x10^6 CD34+ stem cells/kg. Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guidelines.

Location: University of Rochester Medical Center
Study Reference #: UBMT-16009

Lead Researcher (Principal Investigator)

Lead Researcher:  Michael Becker, MD

Study Contact Information

Study Coordinator: katherine Nedrow
Phone: (585) 275-3893
Email: Katherine_Nedrow@URMC.Rochester.edu

Additional Study Details

Return to Search